Background Different bone‐modifying agents like bisphosphonates and receptor activator of
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …

Background In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal
related events associated with bone metastases. However, it is uncertain whether they play …

Most men with advanced prostate cancer will develop bone metastases, which have a
substantial impact on quality of life. Bone metastases can lead to skeletal-related events …

Background The prevalence and incidence of pain and skeletal complications of metastatic
bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is …

Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …

Background Bone metastases are a common complication of prostate cancer, so treatment
and prevention are essential to slow the progression of the disease and the occurrence of …

Abstract Background Bone metastases (BMs) are common in patients with prostate cancer
and can lead to skeletal-related events (SREs), which are associated with increased pain …

Historically, only prostate cancer patients with metastatic disease developed bone
complications. Bone is the primary metastatic site in prostate cancer, with approximately …

Skeletal morbidity is a prominent burden to men with advanced prostate cancer throughout
the natural history of the disease. Bone metastases can cause pain and greatly elevate the …

Simple Summary Over the disease course of metastatic prostate cancer, approximately the
90% of patients develops bone metastases, with bone involvement frequently leading to …